Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2010 1
2011 1
2012 5
2013 6
2014 9
2015 7
2016 5
2017 5
2018 4
2019 5
2020 4
2021 7
2022 9
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Scoring Abdominal Symptoms in People with Cystic Fibrosis.
Tabori H, Barucha A, Zagoya C, Duckstein F, Dunay GA, Sadrieh P, Polte L, Mainz JG. Tabori H, et al. Among authors: mainz jg. J Clin Med. 2024 Mar 13;13(6):1650. doi: 10.3390/jcm13061650. J Clin Med. 2024. PMID: 38541878 Free PMC article. Review.
[CF Lung Disease - a German S3 Guideline: Pseudomonas aeruginosa].
Schwarz C, Bend J, Hebestreit H, Hogardt M, Hügel C, Illing S, Mainz JG, Rietschel E, Schmidt S, Schulte-Hubbert B, Sitter H, Wielpütz MO, Hammermann J, Baumann I, Brunsmann F, Dieninghoff D, Eber E, Ellemunter H, Eschenhagen P, Evers C, Gruber S, Koitschev A, Ley-Zaporozhan J, Düesberg U, Mentzel HJ, Nüßlein T, Ringshausen FC, Sedlacek L, Smaczny C, Sommerburg O, Sutharsan S, Vonberg RP, Weber AK, Zerlik J. Schwarz C, et al. Among authors: mainz jg. Pneumologie. 2024 Feb 29. doi: 10.1055/a-2278-6685. Online ahead of print. Pneumologie. 2024. PMID: 38423036 German. No abstract available.
[CF Lung Disease - a German S3 Guideline: Pseudomonas aeruginosa].
Schwarz C, Bend J, Hebestreit H, Hogardt M, Hügel C, Illing S, Mainz JG, Rietschel E, Schmidt S, Schulte-Hubbert B, Sitter H, Wielpütz MO, Hammermann J, Baumann I, Brunsmann F, Dieninghoff D, Eber E, Ellemunter H, Eschenhagen P, Evers C, Gruber S, Koitschev A, Ley-Zaporozhan J, Düesberg U, Mentzel HJ, Nüßlein T, Ringshausen FC, Sedlacek L, Smaczny C, Sommerburg O, Sutharsan S, Vonberg RP, Weber AK, Zerlik J. Schwarz C, et al. Among authors: mainz jg. Pneumologie. 2024 Feb 13. doi: 10.1055/a-2182-1907. Online ahead of print. Pneumologie. 2024. PMID: 38350639 Free article. German.
ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis.
Wilschanski M, Munck A, Carrion E, Cipolli M, Collins S, Colombo C, Declercq D, Hatziagorou E, Hulst J, Kalnins D, Katsagoni CN, Mainz JG, Ribes-Koninckx C, Smith C, Smith T, Van Biervliet S, Chourdakis M. Wilschanski M, et al. Among authors: mainz jg. Clin Nutr. 2024 Feb;43(2):413-445. doi: 10.1016/j.clnu.2023.12.017. Epub 2023 Dec 27. Clin Nutr. 2024. PMID: 38169175
Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire.
Mainz JG, Barucha A, Huang P, Bechinger L, Duckstein F, Polte L, Sadrieh P, Nährlich L, Eickmeier O, Van Dullemen S, Eschenhagen P, Schwarz C, Lüth S, Zagoya C, Graepler-Mainka U. Mainz JG, et al. Front Pharmacol. 2023 Oct 25;14:1167407. doi: 10.3389/fphar.2023.1167407. eCollection 2023. Front Pharmacol. 2023. PMID: 38026920 Free PMC article.
Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years - The RECOVER study.
Mainz JG, Lester K, Elnazir B, Williamson M, McKone E, Cox D, Linnane B, Zagoya C, Duckstein F, Barucha A, Davies JC, McNally P; RECOVER Study Group. Mainz JG, et al. J Cyst Fibros. 2023 Oct 7:S1569-1993(23)00922-0. doi: 10.1016/j.jcf.2023.10.001. Online ahead of print. J Cyst Fibros. 2023. PMID: 37806792
Proliferative activity of antigen-specific CD154+ T cells against bacterial and fungal respiratory pathogens in cystic fibrosis decreases after initiation of highly effective CFTR modulator therapy.
Eschenhagen PN, Bacher P, Grehn C, Mainz JG, Scheffold A, Schwarz C. Eschenhagen PN, et al. Among authors: mainz jg. Front Pharmacol. 2023 Jun 20;14:1180826. doi: 10.3389/fphar.2023.1180826. eCollection 2023. Front Pharmacol. 2023. PMID: 37408761 Free PMC article.
Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score.
Mainz JG, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, Smaczny C, Barucha A, Bechinger L, Duckstein F, Kurzidim L, Eschenhagen P, Caley L, Peckham D, Schwarz C. Mainz JG, et al. Front Pharmacol. 2023 May 3;14:1207356. doi: 10.3389/fphar.2023.1207356. eCollection 2023. Front Pharmacol. 2023. PMID: 37205908 Free PMC article.
The Cystic Fibrosis Upper and Lower Airway Metagenome.
Pienkowska K, Pust MM, Gessner M, Gaedcke S, Thavarasa A, Rosenboom I, Morán Losada P, Minso R, Arnold C, Hedtfeld S, Dorda M, Wiehlmann L, Mainz JG, Klockgether J, Tümmler B. Pienkowska K, et al. Among authors: mainz jg. Microbiol Spectr. 2023 Mar 9;11(2):e0363322. doi: 10.1128/spectrum.03633-22. Online ahead of print. Microbiol Spectr. 2023. PMID: 36892308 Free PMC article.
73 results